Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK206136 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | GSK206136 once daily |
| Placebo | PLACEBO_COMPARATOR | Placebo once daily |
| Name | Type | Description |
|---|---|---|
| GSK206136 | DRUG | GSK206136 2mg, 10mg, 50mg, 100mg capsule |
| PLACEBO | DRUG | Placebo to match 206136 2mg, 10mg, 50mg, 100mg capsule |
| PET | RADIATION | Each subject will undergo 3 PET Scans ; one at Baseline and the others following dosing with GSK206136 at approximately 2 hours post-dose and 24 hours post-dose |
Inclusion Criteria: * Healthy males aged 18-45 years, limited to 25-40 years of age for PET section Exclusion Criteria: * The subject has a positive: drug/alcohol, Hepatitis, HIV screen.. * The subject has a history of psychiatric illness suicidal attempts or behaviour. * Abuse of alcohol. * Clin...
GSK206136 is an investigational small molecule being studied for the treatment of Depressive Disorder and Anxiety Disorders. It is in Phase 1 clinical development and has not been approved by regulatory authorities.
GSK206136 is being developed by GSK plc, a pharmaceutical company traded on the stock exchange under the ticker GSK.
GSK206136 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. A Phase 1 study has been completed.
GSK206136 has one completed Phase 1 trial, NCT01059578, titled 'First Study in Humans With GSK206136'. This trial enrolled 33 participants in the United Kingdom and was a randomized, double-blind, placebo-controlled study.
No alternative names for GSK206136 have been reported. It is identified solely by its code name GSK206136 in clinical trial records.